Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract
In contemporary practice, many patients receive ARPI intensification in the metastatic hormone-sensitive or nonmetastatic castration-resistant setting, leading to questions regarding the value of subsequent ARPI rechallenge once mCRPC develops. Although ARPI reuse remains common in routine practice, particularly among older patients or those who may not be candidates for chemotherapy, there is growing recognition that cross-resistance between ARPIs may limit the benefit of sequential hormonal therapy. In this context, cabazitaxel has emerged as an important option given its demonstrated activity in patients previously treated with docetaxel and ARPI, as supported by prospective randomized data.
Our findings reinforce the concept that cabazitaxel may provide improved outcomes compared with subsequent ARPI use in selected patients after progression on docetaxel and prior ARPI exposure. While treatment selection in the real world remains influenced by factors such as age, performance status, comorbidities, and patient preference, these results add to the growing body of evidence suggesting that chemotherapy should not be deferred solely because an additional hormonal option is available. Importantly, this analysis also highlights the need for better biomarkers and clinical tools to guide sequencing decisions in advanced prostate cancer. Future studies should focus on identifying which patients may still derive benefit from ARPI rechallenge versus those more likely to benefit from earlier cabazitaxel, radioligand therapy, PARP inhibition, or clinical trial enrollment.
Written by: Pedro C. Barata, MD, MSc, FACP, Miggo Family Chair in Cancer Research, Co-Leader Genitourinary (GU) Disease Team, Director of GU Medical Oncology Research Program, University Hospitals Seidman Cancer Center, Associate Professor of Medicine, Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, OH
Read the Abstract